Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Organon (OGN) Stock Dips While Market Gains: Key Facts
07:06pm, Wednesday, 02'nd Oct 2024
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
Final Trades: Organon, Howmet and the PSQ
01:35pm, Wednesday, 02'nd Oct 2024
The Investment Committee give you their top stocks to watch for the second half.
Why Organon (OGN) Outpaced the Stock Market Today
07:05pm, Thursday, 26'th Sep 2024
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:00am, Wednesday, 25'th Sep 2024
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
03:20pm, Wednesday, 18'th Sep 2024
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Roivant Flips a Skin Drug to Organon
10:59am, Wednesday, 18'th Sep 2024
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to buy therapy developer Dermavant for up to $1.2 billion
07:39am, Wednesday, 18'th Sep 2024
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
07:30am, Wednesday, 18'th Sep 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Organon (OGN) Outperforms Broader Market: What You Need to Know
06:56pm, Friday, 13'th Sep 2024
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
10:00am, Thursday, 12'th Sep 2024
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
01:46pm, Friday, 06'th Sep 2024
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be d
Is Trending Stock Organon & Co. (OGN) a Buy Now?
10:01am, Wednesday, 28'th Aug 2024
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
10:02am, Wednesday, 14'th Aug 2024
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
12:01pm, Tuesday, 06'th Aug 2024
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street es
Organon (OGN) Surpasses Q2 Earnings Estimates
09:56am, Tuesday, 06'th Aug 2024
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
